Craciun M, et al. - Data from consecutive 170 subjects with overactive bladder (OAB) symptoms due to urodynamically-proven idiopathic detrusor overactivity who had failed maximum-dose pharmacotherapy and bladder drill was analyzed by the researchers in order to present the outcomes of active management protocol for bothersome OAB symptoms via abobotulinumtoxinA (Dysport) over a 9-year period. The results of 299 treatments were assessed. Improvement by a mean of 35% and 41% of Overactive Bladder Symptom Score (OABSS) and quality of life indices, respectively, was noted with the OABSS improving by 2 or more points in 65% of cases. The severity of incontinence was decreased in 44% of the cases, while urgency incontinence was completely eliminated in 26%. After a mean of 10.2 months, pharmacotherapy was continued, and the mean interval between repeat abobotulinumtoxinA injection treatments was 21.3 months. Because of the high postvoid residuals, de-novo self-catheterization was needed in 18.2% of cases. Hence, for subjects with refractory OAB symptoms, the use of abobotulinumtoxinA was a safe and highly efficient treatment of choice. Moreover, in terms of symptom score improvement and self-catheterization rates, alike outcomes to onabotulinumtoxinA were observed.